East Coast insurer now covers tibial nerve stimulation for OAB
Uroplasty, Inc. has announced that EmblemHealth now covers percutaneous tibial nerve stimulation using the company's Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.
Uroplasty, Inc. has announced that EmblemHealth now covers percutaneous tibial nerve stimulation using the company’s Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.
EmblemHealth covers approximately two million lives primarily in New York and New Jersey and includes Group Health Inc. and the Health Plan of New York.
“This expanded private payer coverage increases access for OAB patients to percutaneous tibial nerve stimulation treatments and the opportunity to receive this innovative, minimally invasive, and clinically effective therapy. The additional coverage provides physicians in the Northeast with another treatment option for their OAB patients,” said David Kaysen, president and CEO of Uroplasty.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
